*Th17/IL-17, Immunometabolism and Psoriatic Disease: A Pathological Trifecta DOI: http://dx.doi.org/10.5772/intechopen.102633*

inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance. Inflammation. 2022;**45**(1):31-44

[79] Rijnsburger M, Djuric N, Mulder IA, de Vries HE. Adipokines as immune cell modulators in multiple sclerosis. International Journal of Molecular Sciences. 2021;**22**(19):10845. DOI: 10.3390/ijms221910845

[80] Gerriets VA, Danzaki K, Kishton RJ, Eisner W, Nichols AG, Saucillo DC, et al. Leptin directly promotes T-cell glycolytic metabolism to drive effector T-cell differentiation in a mouse model of autoimmunity. European Journal of Immunology. 2016;**46**(8):1970-1983

[81] Su X, Zhang G, Cheng Y, Wang B. Leptin in skin disease modulation. Clinica Chimica Acta. 2021;**516**:8-14

[82] Su X, Cheng Y, Chang D. The important role of leptin in modulating the risk of dermatological diseases. Frontiers in Immunology. 2021;**11**: 593564. DOI: 10.3389/fimmu.2020. 593564

[83] Li Y, Yang Q, Cai D, Guo H, Fang J, Cui H, et al. Resistin, a novel host defense peptide of innate immunity. Frontiers in Immunology. 2021;**12**:699807. DOI: 10.3389/fimmu.2021.699807

[84] Lee M-J, Wu Y, Fried SK. Adipose tissue remodeling in pathophysiology of obesity. Current Opinion in Clinical Nutrition and Metabolic Care. 2010;**13**(4):371-376

[85] Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: A populationbased study in the United Kingdom. The Journal of Investigative Dermatology. 2012;**132**(3):556-562

[86] Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: A multicentre longitudinal cohort study. The British Journal of Dermatology. 2019;**180**(5):1069-1076

[87] Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: A systematic review and dose–response meta-analysis of prospective studies. European Journal of Epidemiology. 2018;**33**(12):1163-1178

[88] Hwang J, Yoo JA, Yoon H, Han T, Yoon J, An S, et al. The role of leptin in the association between obesity and psoriasis. Biomolecules & Therapeutics. 2021;**29**(1):11-21

[89] Dopytalska K, Baranowska-Bik A, Roszkiewicz M, Bik W, Walecka I. The role of leptin in selected skin diseases. Lipids in Health and Disease. 2020;**19**(1):1-10

[90] Yamazaki F. Psoriasis: Comorbidities. The Journal of Dermatology. 2021;**48**(6):732-740

[91] Ruiyang B, Panayi A, Ruifang W, Peng Z, Siqi F. Adiponectin in psoriasis and its comorbidities: A review. Lipids in Health and Disease. 2021;**20**(1):1-11

[92] Shibata S, Tada Y, Hau CS, Mitsui A, Kamata M, Asano Y, et al. Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells. Nature Communications. 2015;**6**(1):1-14

[93] Surendar J, Frohberger SJ, Karunakaran I, Schmitt V, Stamminger W, Neumann A-L, et al. Adiponectin limits IFN-γ and IL-17 producing CD4 T cells in obesity by restraining cell

intrinsic glycolysis. Frontiers in Immunology. 2019;**10**:2555. DOI: 10.3389/ fimmu.2019.02555

[94] Michelet X, Dyck L, Hogan A, Loftus RM, Duquette D, Wei K, et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nature Immunology. 2018;**19**(12):1330-1340

[95] Koussiouris J, Looby N, Anderson M, Kulasingam V, Chandran V. Metabolomics studies in psoriatic disease: A review. Metabolites. 2021;**11**(6): 375. DOI: 10.3390/metabo11060375

[96] Sorokin AV, Domenichiello AF, Dey AK, Yuan Z-X, Goyal A, Rose SM, et al. Bioactive lipid mediator profiles in human psoriasis skin and blood. The Journal of Investigative Dermatology. 2018;**138**(7):1518-1528

[97] Sorokin AV, Norris PC, English JT, Dey AK, Chaturvedi A, Baumer Y, et al. Identification of proresolving and inflammatory lipid mediators in human psoriasis. Journal of Clinical Lipidology. 2018;**12**(4):1047-1060

[98] Dutkiewicz EP, Hsieh K-T, Urban PL, Chiu H-Y. Temporal correlations of skin and blood metabolites with clinical outcomes of biologic therapy in psoriasis. Journal of Applied Laboratory Medicine. 2020;**5**(5):877-888

[99] Tarentini E, Odorici G, Righi V, Paganelli A, Giacomelli L, Mirisola V, et al. Integrated metabolomic analysis and cytokine profiling define clusters of immuno-metabolic correlation in new-onset psoriasis. Scientific Reports. 2021;**11**(1):1-12

[100] Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. The New England Journal of Medicine. 2016;**375**(24):2369-2379

[101] Chen L, Li J, Zhu W, Kuang Y, Liu T, Zhang W, et al. Skin and gut microbiome in psoriasis: Gaining insight into the pathophysiology of it and finding novel therapeutic strategies. Frontiers in Microbiology. 2020;**11**:589726. DOI: 10.3389/fmicb.2020.589726

[102] Aydin B, Arga KY, Karadag AS. Omics-driven biomarkers of psoriasis: Recent insights, current challenges, and future prospects. Clinical, Cosmetic and Investigational Dermatology. 2020;**13**:611-625. DOI: 10.2147/CCID. S227896

[103] Liu Y, Cui S, Sun J, Yan X, Han D. Identification of potential biomarkers for psoriasis by DNA methylation and gene expression datasets. Frontiers in Genetics. 2021;**12**:722803. DOI: h10.3389/ fgene.2021.722803

[104] Su W, Wei Y, Huang B, Ji J. Identification of hub genes and immune infiltration in psoriasis by bioinformatics method. Frontiers in Genetics. 2021;**12**:606065. DOI: 10.3389/ fgene.2021.606065

**Chapter 5**
